Global Markets Direct’s, 'Hypercalcemia - Pipeline Review, H2 2012', provides an overview of the Hypercalcemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercalcemia. 'Hypercalcemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Hypercalcemia. - A review of the Hypercalcemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hypercalcemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hypercalcemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hypercalcemia pipeline depth and focus of Hypercalcemia therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Hypercalcemia - Pipeline Review, H2 2012 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hypercalcemia Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Hypercalcemia 7 Hypercalcemia Therapeutics under Development by Companies 9 Hypercalcemia Therapeutics under Investigation by Universities/Institutes 10 Mid Clinical Stage Products 11 Comparative Analysis 11 Early Clinical Stage Products 12 Comparative Analysis 12 Hypercalcemia Therapeutics - Products under Development by Companies 13 Hypercalcemia Therapeutics - Products under Investigation by Universities/Institutes 14 Companies Involved in Hypercalcemia Therapeutics Development 15 Genta Incorporated 15 Med Discovery SA 16 Hypercalcemia - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Drug Profiles 22 G4544 - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 Parathyroid Hormone (1-34) - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 MDAB16 - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 Hypercalcemia Therapeutics - Dormant Products 26 Hypercalcemia - Product Development Milestones 27 Featured News and Press Releases 27 Dec 02, 2009: Genta to Support Initiation of New Clinical Trial using Ganite as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis 27 Jun 04, 2007: Phase 2 Clinical Results of Ganiteandreg; Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO 27 Mar 07, 2007: Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganiteandreg; and Genasenseandreg; 28 Mar 02, 2006: Randomized Trial Shows Ganiteandreg; Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia 29 Dec 23, 2004: NPS Completes $175 Million Note Offering Backed By Sensipar Royalties 29 Dec 05, 2004: Ganiteandreg; Activity in Patients with Advanced Non-Hodgkin's Lymphoma Presented at Hematology Meeting 30 Jul 30, 2004: Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion For Approval In Europe 30 Apr 08, 2004: Sensipar Pivotal Studies In Over 700 Patients Published In New England Journal Of Medicine 31 Mar 25, 2004: GenasenseTM and GaniteTM Featured in Presentations at the Annual Meeting of the American Association for Cancer Research 32 Sep 18, 2003: FDA Approves Genta's First Product, Ganite, for the Treatment of Cancer - Related Hypercalcemia 32 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables
Number of Products Under Development for Hypercalcemia, H2 2012 7 Products under Development for Hypercalcemia - Comparative Analysis, H2 2012 8 Number of Products under Development by Companies, H2 2012 9 Number of Products under Investigation by Universities/Institutes, H2 2012 10 Comparative Analysis by Mid Clinical Stage Development, H2 2012 11 Comparative Analysis by Early Clinical Stage Development, H2 2012 12 Products under Development by Companies, H2 2012 13 Products under Investigation by Universities/Institutes, H2 2012 14 Genta Incorporated, H2 2012 15 Med Discovery SA, H2 2012 16 Assessment by Monotherapy Products, H2 2012 17 Assessment by Stage and Route of Administration, H2 2012 19 Assessment by Stage and Molecule Type, H2 2012 21 Hypercalcemia Therapeutics - Dormant Products 26
List of Figures
Number of Products under Development for Hypercalcemia, H2 2012 7 Products under Development for Hypercalcemia - Comparative Analysis, H2 2012 8 Products under Development by Companies, H2 2012 9 Products under Investigation by Universities/Institutes, H2 2012 10 Mid Clinical Stage Products, H2 2012 11 Early Clinical Stage Products, H2 2012 12 Assessment by Monotherapy Products, H2 2012 17 Assessment by Route of Administration, H2 2012 18 Assessment by Stage and Route of Administration, H2 2012 19 Assessment by Molecule Type, H2 2012 20 Assessment by Stage and Molecule Type, H2 2012 21